EU approval for Resolor (prucalopride) extended to male patients with chronic constipation-Shire plc

Shire plc announced that Resolor (prucalopride) has been approved by the European Medicines Agency for use in adults for the symptomatic treatment of chronic constipation in whom laxatives fail to provide adequate relief. Resolor is approved for use in women in Europe, so the new variation extends the use of this treatment to male patients. Chronic constipation is characterised by infrequent and difficult passage of stools over a prolonged period, and includes a range of symptoms. It is estimated to affect up to 14% of the population, with an incidence rate of 17% in women and 9% in men. It is often a persistent condition that can impact significantly on a patient’s quality of life. Resolor is a selective, high-affinity 5-HT4 receptor agonist, which helps to stimulate bowel motility.

 

Comment:In contrast to laxatives, prucalopride triggers a physiological and peristaltic reflex in the colon through stimulation of the 5HT4-receptors on the intramural nerves. This accelerates overall transit along the GI tract, induces colonic mass movement and significantly enhances colonic emptying. Prucalopride stimulates normal bowel function by specifically targeting the underlying impaired motility and as a result it alleviates a broad range of chronic constipation symptoms and improves patient satisfaction..